Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for hard-to-treat lymphoma: experimental drug enters human testing

NCT ID NCT06470438

Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 4 times

Summary

This early-stage study tests a new oral drug, JNJ-88998377, in about 58 people with relapsed or refractory B-cell non-Hodgkin's lymphoma (a type of blood cancer). The main goals are to check the drug's safety and find the best dose for future studies. Participants must have measurable disease and be in relatively good health (ECOG 0 or 1).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

58 people

The number who actually took part.

Started

May 2024

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants have histologically or cytologically confirmed B-cell non-Hodgkin's Lymphoma (NHL) according to the 2022 World Health Organization (WHO) classification with relapsed or refractory disease * Participants have measurable disease or meet all requirements for adequate response assessment as defined by the appropriate disease response criteria at screening * Participants have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Participants have a life expectancy of greater than or equal to (\>=) 12 weeks * Be willing and able to adhere to the lifestyle restrictions specified in the protocol Exclusion Criteria: * Participant with active or prior history of B-cell NHL involving the central nervous system (CNS) and leptomeningeal involvement * History of malignancy (other than the disease under study in the cohort to which the participant is assigned) within 1 year prior to the first administration of study treatment. * For Part A and B: Participant having known allergies, hypersensitivity, or intolerance to the excipients of JNJ-88998377 * Participant had major surgery or had significant traumatic injury within 30 days before first dose of study treatment or has not recovered from surgery and must not have major surgery planned during the time the participant is receiving study treatment * Participant received an autologous stem cell transplant less than or equal to (\<=) 3 months before the first dose of study treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lymphoma, non-Hodgkin are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma lymphoma, non-Hodgkin, familial non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphoma, non-Hodgkin Refractory B-cell NHL Relapsed B-cell NHL

Contacts and locations

Locations

  • A O U Sant Orsola Malpighi

    Bologna, 40138, Italy

  • Aidport Sp z o o

    Skorzewo, 60-185, Poland

  • Ankara Universitesi Hastaneleri Tibbi Farmakoloji Anabilim Dali Faz 1 Klinik Arastirma Merkezi

    Ankara, 06620, Turkey (Türkiye)

  • Beijing Cancer Hospital

    Beijing, 100142, China

  • Fudan University Shanghai Cancer Center

    Shanghai, 200032, China

  • Koc Universitesi Hastanesi Faz 1 Klinik Arastirma Merkezi

    Istanbul, 34010, Turkey (Türkiye)

  • Linkou Chang Gung Memorial Hospital

    Taoyuan, 33382, Taiwan

  • National Cancer Center Hospital

    Chūōku, 104 0045, Japan

  • National Cancer Center Hospital East

    Kashiwa, 277-8577, Japan

  • National Taiwan University Hospital

    Taipei, 10043, Taiwan

  • Pratia Onkologia Katowice

    Katowice, 40 519, Poland

  • SBU Ankara Dr. Abdurrahman Yurtaslan Onkoloji Egitim ve Arastirma Hastanesi Faz 1 Merkezi

    Ankara, 06200, Turkey (Türkiye)

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Sun Yat Sen University Cancer Center

    Guangzhou, 510062, China

  • Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach, Klinika Hematologii i Transplantacji Szpiku

    Kielce, 25-734, Poland

  • The Cancer Institute Hospital of JFCR

    Tokyo, 135 8550, Japan

  • The First Affiliated Hospital Zhejiang University College of Medicine

    Hangzhou, 310002, China

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, 300181, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.